ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0535

Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists

Jasvinder Singh1, John Richards2, Elizabeth Chang3, Toupin-April, Karine Toupin-April4 and Jennifer Barton5, 1University of Alabama at Birmingham, Birmingham, AL, 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 3Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, 4VA Portland Oregon, Portland, OR, 5Oregon University, Portland, OR

Meeting: ACR Convergence 2020

Keywords: Decision analysis, gout, Patient reported outcomes, quality of care, Surveys

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Session Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.

Methods: We performed a cross-sectional electronic survey of rheumatologists at U.S. Veterans Affairs (VA) medical centers, assessing views and practices related to SDM in gout.

Results: Of the 154 VA rheumatology providers eligible, 90 responded (response rate, 58%). Fifty-eight percent were female, the mean age was 51 years (standard deviation, 9.6), 42% had >20 years of experience in medical practice (Table 1).

Rheumatologists reported routinely offering a choice to their patients for: (1) starting urate-lowering therapy (ULT) for gout vs. doing nothing (70%); (2) choosing NSAIDs, corticosteroids, or colchicine for the treatment of acute flares (67%); and (3) choosing NSAIDs, corticosteroids, or colchicine for anti-inflammatory prophylaxis when starting ULT (51%; Appendix 1). Very few rheumatologists offered choice regarding: (4) choosing allopurinol vs. febuxostat as the first ULT (16%); and (5) taking daily ULT long-term vs. intermittently (15%).

Rheumatologists perceived that large proportion of patient were often or sometimes unsure of the best choice for these five decisions, respective proportions were 34%, 76%, 76%, 52%, and 54%. Similar proportions were often or sometimes uninformed about both medication benefits and risks, unclear about the personal importance of the benefits and risks, and unsupported in decision-making (Table 2). The rheumatologists reported that 44-64% of the patients were uninformed about both benefits and risks, 52-73% were unclear about the personal importance of the benefits and risks, and 36-52% were unsupported in decision-making (Table 2).

Conclusion: The majority of VA rheumatologists incorporated SDM in several gout treatment decisions. Rheumatologists also recognized that patients need better support to participate in SDM in gout.

Table 1. Characteristics of survey respondents (n=90 providers)

Appendix 1. Provider practices for choice for the patient regarding gout treatment decisions

Table 2. Provider view of patient difficulties and their role in shared decision-making (SDM) process in gout


Disclosure: J. Singh, Crealta/Horizon, 1, Medisys, 1, Fidia, 1, UBM LLC, 1, Trio health, 1, Medscape, 1, WebMD, 1, Clinical Care options, 1, Clearview healthcare partners, 1, Putnam associates, 1, Focus forward, 1, Navigant consulting, 1, Spherix, 1, Practice Point communications, 1, the National Institutes of Health, 1, the American College of Rheumatology, 1, Amarin pharmaceuticals, 1, Viking therapeutics, 1, OMERACT, 1; J. Richards, None; E. Chang, None; T. Toupin-April, None; J. Barton, None.

To cite this abstract in AMA style:

Singh J, Richards J, Chang E, Toupin-April T, Barton J. Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/provider-opinion-and-support-for-shared-decision-making-in-gout-treatment-a-quality-improvement-national-survey-of-veterans-affairs-rheumatologists/. Accessed June 29, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/provider-opinion-and-support-for-shared-decision-making-in-gout-treatment-a-quality-improvement-national-survey-of-veterans-affairs-rheumatologists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies